Status:
COMPLETED
SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
COVID-19
SARS-CoV 2
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily tra...
Eligibility Criteria
Inclusion
- Participant is a essential worker performing at least some in-person job duties (not 100% remote)
- Participant is willing and able to perform intervention and data collection procedures.
- Participant is able to provide informed consent in English language.
Exclusion
- Diagnosis of COVID-19 within 2 months prior to enrollment, or active respiratory illness symptoms at time of enrollment
- Known medical contraindication to chlorhexidine gluconate or povidone-iodine treatment ingredients (such as a known allergy)
- Participant has a known medical and/or surgical reason prohibiting nasal swab sampling.
- Participant is female who is pregnant, or believes she may be pregnant, at time of enrollment.
- Participant is actively taking/using any treatments or interventions as part of any other COVID-19 related investigational trials.
Key Trial Info
Start Date :
July 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT04478019
Start Date
July 7 2020
End Date
June 30 2022
Last Update
July 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin-Madison
Madison, Wisconsin, United States, 53705